-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Barrett esophagealitis (BE) is a precancer lesions of esophageal adenocarcinoma, which is on the rise, and patients gradually develop from non-hyperpluric endoscopic epithelitis (IM) to low-level atypical hyperplocysis (LGD), highly atypical hyperpluration (HGD) and eventually inflamed cancer.
current international guidelines recommend endoscopic therapy with HGD or early BE endoscopic excision (ER) or radio frequency ablation (RFA).
the purpose of this study was to explore radio frequency ablation (RFA) for reducing Barrett's esopathy researchers by randomly assigning BE patients diagnosed with LGD to RFA or monitoring conservative treatment groups.
observational outcome was the rate at which BE patients progressed to highly atypical growth (HGD)/cancer.
136 patients were randomly assigned to the RFA (n s 68) or monitoring (n s 68) group in this study.
study, 15 patients monitored were analyzed for the risk of RFA cancer based on their preferences and findings.
study showed that the medium follow-up time from random grouping to the last endoscopy was 73 months.
1 patient (1.5%) in the RFA group was finally diagnosed with HGD/cancer, and 23 (33.8%) in the monitoring group were diagnosed with HGD/cancer (P s .0001), thus reducing the absolute risk by 32.4% (95% confidence interval (CI), 22.4%-44.2%).
83 patients treated with RFA (90%; 95% CI, 82.1%-95.0%) achieved BE's complete removal and atypical growth.
7 out of 75 patients (9%; 95% CI, 4.6%-18.0%) relapsed.
study confirmed that BE patients with LGD significantly reduced the risk of malignant progressity after RFA.
.